PSMA PET imaging’s proliferation produces uptick in aggressive treatment for prostate cancer
First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer.
First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
